Through two separate grants, Dr. Bhardwaj is exploring two strategies to make immunotherapy even more effective for patients.
Through her CLIP Grant, she is analyzing patient samples to determine how Poly ICLC (a TLR agonist) affects the tumor environment and immune responses against specific mutations, to identify how Poly ICLC could complement existing immunotherapies.
Through her Clinical Team Grant, Dr. Bhardwaj and Sacha Gnjatic, Ph.D., are investigating the relationship between checkpoint immunotherapy, chemotherapy, and mutations in advanced bladder cancer, to guide vaccine development and inform combination treatment approaches. Their next steps are to characterize how these treatments affected NK cell function as well as determine the reactivity of patients’ T cells against tumor mutations.
Projects and Grants
The mutation-derived tumor antigen landscape of advanced bladder cancer: A platform to optimize cancer immunotherapy
Icahn School of Medicine at Mount Sinai | Bladder Cancer | 2015
Analysis of immune responses induced by in situ, autologous therapeutic vaccination against solid cancers with intratumoral hiltonol (Poly-ICLC).
Icahn School of Medicine at Mount Sinai | Melanoma, Sarcoma | 2016
Let's spread the word about Immunotherapy! Click to share this page with your community.